 Equillium, Inc. EQ, a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced it has entered into a common stock purchase agreement for up to 15 million with Lincoln Park Capital Fund, LLC LPC, a Chicago-based institutional investor. Under the terms of the purchase agreement, and once a registration statement relating to the transaction has been declared effective, Equillium will have the right at its sole discretion, but not the obligation, to sell to LPC up to 15 million worth of shares of its common stock over the 36-month term of the agreement. 